{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:14:46Z","timestamp":1775693686272,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:00:00Z","timestamp":1579564800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:00:00Z","timestamp":1579564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sant\u00e9 Publique France","award":["CNR Paludisme"],"award-info":[{"award-number":["CNR Paludisme"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The drug combination atovaquone\u2013proguanil, is recommended for treatment of uncomplicated falciparum malaria in France. Despite high efficacy, atovaquone\u2013proguanil treatment failures have been reported. Resistance to cycloguanil, the active metabolite of proguanil, is conferred by multiple mutations in the <jats:italic>Plasmodium falciparum<\/jats:italic> dihydrofolate reductase (<jats:italic>pfdhfr<\/jats:italic>) and resistance to atovaquone by single mutation on codon 268 of the cytochrome b gene (<jats:italic>pfcytb<\/jats:italic>).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 47-year-old female, native from Congo and resident in France, was admitted in hospital for uncomplicated falciparum malaria with parasitaemia of 0.5%, after travelling in Congo (Brazzaville and Pointe Noire). She was treated with atovaquone\u2013proguanil (250\u00a0mg\/100\u00a0mg) 4 tablets daily for 3 consecutive days. On day 5 after admission she was released home. However, many weeks after this episode, without having left France, she again experienced fever and intense weakness. On day 39 after the beginning of treatment, she consulted for fever, arthralgia, myalgia, photophobia, and blurred vision. She was hospitalized for uncomplicated falciparum malaria with a parasitaemia of 0.375% and treated effectively by piperaquine\u2013artenimol (320\u00a0mg\/40\u00a0mg) 3 tablets daily for 3 consecutive days. Resistance to atovaquone\u2013proguanil was suspected. The Y268C mutation was detected in all of the isolates tested (D39, D42, D47). The genotyping of the <jats:italic>pfdhfr<\/jats:italic> gene showed a triple mutation (N51I, C59R, S108N) involved in cycloguanil resistance.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This is the first observation of a late clinical failure of atovaquone\u2013proguanil treatment of <jats:italic>P. falciparum<\/jats:italic> uncomplicated malaria associated with <jats:italic>pfcytb<\/jats:italic> 268 mutation in a traveller returning from Congo. These data confirm that the Y268C mutation is associated with delayed recrudescence 4\u00a0weeks or more after initial treatment. Although atovaquone\u2013proguanil treatment failures remain rare, an increased surveillance is required. It is essential to declare and publish all well-documented cases of treatment failures because it is the only way to evaluate the level of resistance to atovaquone.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12936-020-3126-y","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T16:02:39Z","timestamp":1579622559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Late clinical failure associated with cytochrome b codon 268 mutation during treatment of falciparum malaria with atovaquone\u2013proguanil in traveller returning from Congo"],"prefix":"10.1186","volume":"19","author":[{"given":"Laurencie","family":"Massamba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marylin","family":"Madamet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Benoit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Fonta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Mondain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Yves","family":"Jeandel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9my","family":"Amalvict","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Delaunay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Mosnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Marty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Pomares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Pradines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,21]]},"reference":[{"key":"3126_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2019.07.011","author":"L Epelboin","year":"2019","unstructured":"Epelboin L, Rapp C, Faucher JF, M\u00e9cha\u00ef F, Bottieau E, Matheron S, et al. Management and treatment of uncomplicated imported malaria in adults. Update of the French malaria clinical guidelines. Med Mal Infect. 2019. https:\/\/doi.org\/10.1016\/j.medmal.2019.07.011.","journal-title":"Med Mal Infect"},{"key":"3126_CR2","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1128\/AAC.00282-08","volume":"52","author":"H Savini","year":"2008","unstructured":"Savini H, Bogreau H, Bertaux L, Bouchiba H, Kraemer P, Parzy D, et al. First case of emergence of atovaquone\u2013proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros. Antimicrob Agents Chemother. 2008;52:2283\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"3126_CR3","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1016\/j.micinf.2006.07.011","volume":"8","author":"L Musset","year":"2006","unstructured":"Musset L, Bouchaud O, Matheron S, Massias L, Le Bras J. Clinical atovaquone\u2013proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. Microbes Infect. 2006;8:2599\u2013604.","journal-title":"Microbes Infect"},{"key":"3126_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/jac\/dki420","volume":"57","author":"L Musset","year":"2006","unstructured":"Musset L, Pradines B, Parzy D, Durand D, Bigot P, Le Bras J. Apparent absence of atovaquone\/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. J Antimicrob Chemother. 2006;57:110\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"3126_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/1475-2875-7-240","volume":"7","author":"CJ Sutherland","year":"2008","unstructured":"Sutherland CJ, Laundy M, Price N, Burke M, Fivelman QL, Pasvol G, et al. Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone\u2013proguanil. Malar J. 2008;7:240.","journal-title":"Malar J"},{"key":"3126_CR6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/1475-2875-11-146","volume":"11","author":"N Wurtz","year":"2012","unstructured":"Wurtz N, Pascual A, Marin-Jauffre A, Bouchiba H, Benoit N, Desbordes M, et al. Early treatment failure during treatment of Plasmodium falciparum malaria with atovaquone\u2013proguanil in the Republic of Ivory Coast. Malar J. 2012;11:146.","journal-title":"Malar J."},{"key":"3126_CR7","first-page":"e10","volume":"3","author":"TL Perry","year":"2009","unstructured":"Perry TL, Pandey P, Grant JM, Kain KC. Severe atovaquone-resistant Plasmodium falciparum malaria in a Canadian traveller returned from the Indian subcontinent. Open Med. 2009;3:e10\u20136.","journal-title":"Open Med."},{"key":"3126_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4269\/ajtmh.2005.72.407","volume":"72","author":"S Kuhn","year":"2005","unstructured":"Kuhn S, Gill MJ, Kain KC. Emergence of atovaquone\u2013proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa. Am J Trop Med Hyg. 2005;72:407\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"3126_CR9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1086\/375599","volume":"37","author":"E Schwartz","year":"2003","unstructured":"Schwartz E, Bujanover S, Kain KC. Genetic confirmation of atovaquone\u2013proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin Infect Dis. 2003;37:450\u20131.","journal-title":"Clin Infect Dis"},{"key":"3126_CR10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/INF.0b013e318167918d","volume":"27","author":"GW Rose","year":"2008","unstructured":"Rose GW, Suh KN, Kain KC, Le Saux N, McCarthy AE. Atovaquone\u2013proguanil resistance in imported falciparum malaria in a young child. Pediatr Infect Dis J. 2008;27:567\u20139.","journal-title":"Pediatr Infect Dis J."},{"key":"3126_CR11","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1136\/bmj.326.7390.628","volume":"326","author":"A F\u00e4rnert","year":"2003","unstructured":"F\u00e4rnert A, Lindberg J, Gil P, Swedberg G, Berqvist Y, Thapar MM, et al. Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ. 2003;326:628\u20139.","journal-title":"BMJ"},{"key":"3126_CR12","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1093\/molbev\/msm087","volume":"24","author":"L Musset","year":"2007","unstructured":"Musset L, Le Bras J, Clain J. Parallel evolution of adaptative mutations in Plasmodium falciparum mitochondrial DNA during atovaquone\u2013proguanil treatment. Mol Biol Evol. 2007;24:1582\u20135.","journal-title":"Mol Biol Evol"},{"key":"3126_CR13","doi-asserted-by":"publisher","first-page":"ofu059","DOI":"10.1093\/ofid\/ofu059","volume":"1","author":"MM Plucinski","year":"2014","unstructured":"Plucinski MM, Huber CS, Akinyi S, Dalton W, Eschete M, Grady K, et al. Novel mutation in cytochrome B of Plasmodium falciparum in one of two atovaquone\u2013proguanil treatment failures in travelers returning from same site in Nigeria. Open Forum Infect Dis. 2014;1:ofu059.","journal-title":"Open Forum Infect Dis"},{"key":"3126_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2875-1-1","volume":"1","author":"QL Fivelman","year":"2002","unstructured":"Fivelman QL, Butcher GA, Adagu IS, Warhurst DC, Pasvol G. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malar J. 2002;1:1.","journal-title":"Malar J"},{"key":"3126_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1475-2875-3-14","volume":"3","author":"O Wichmann","year":"2004","unstructured":"Wichmann O, Muehlen M, Gruss H, Mockenhaupt FP, Suttorp N, Jelinek T. Malarone treatment failure not associated with previously described mutations in the cytochrome b gene. Malar J. 2004;3:14.","journal-title":"Malar J"},{"key":"3126_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.lpm.2016.11.018","volume":"46","author":"C Aur\u00e9gan","year":"2017","unstructured":"Aur\u00e9gan C, Argy N, Hubert V, Aprahamian A, Clain J, Cheron G. R\u00e9sistance acquise \u00e0 l\u2019atovaquone\u2013proguanil dans un cas import\u00e9 d\u2019acc\u00e8s palustre simple \u00e0 Plasmodium falciparum chez un jeune enfant. Presse Med. 2017;46:344\u20136.","journal-title":"Presse Med"},{"key":"3126_CR17","doi-asserted-by":"publisher","first-page":"646","DOI":"10.4269\/ajtmh.1997.57.646","volume":"57","author":"D Parzy","year":"1997","unstructured":"Parzy D, Doerig C, Pradines B, Rico A, Fusai T, Doury C. Proguanil resistance in Plasmodium falciparum African isolates: assessment by mutation-specific polymerase chain reaction and in vitro susceptibility testing. Am J Trop Med Hyg. 1997;57:646\u201350.","journal-title":"Am J Trop Med Hyg"},{"key":"3126_CR18","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/jac\/dkx431","volume":"73","author":"HM Staines","year":"2018","unstructured":"Staines HM, Burrows R, Teo BH, Chis Ster I, Kremsner PG, Krishna S. Clinical implications of Plasmodium resistance to atovaquone\/proguanil: a systematic review and meta-analysis. J Antimicrob Chemother. 2018;73:581\u201395.","journal-title":"J Antimicrob Chemother"},{"key":"3126_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.4269\/ajtmh.2007.77.431","volume":"77","author":"P Parola","year":"2007","unstructured":"Parola P, Pradines B, Simon F, Carlotti MP, Minodier P, Ranjeva MP, et al. Antimalarial drug susceptibility and point mutations associated with drug resistance in 248 Plasmodium falciparum isolates imported from Comoros to Marseille, France in 2004 2006. Am J Top Med Hyg. 2007;77:431\u20137.","journal-title":"Am J Top Med Hyg"},{"key":"3126_CR20","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.ijantimicag.2017.01.032","volume":"49","author":"M Madamet","year":"2017","unstructured":"Madamet M, Kounta MB, Wade KA, Lo G, Diawara S, Fall M, et al. Absence of association between polyporphisms in the K13 gene and the presence of Plasmodium falciparum parasites at day 3 after treatment with artemisinin derivatives in Senegal. Int J Antimicrob Agents. 2017;49:754\u20136.","journal-title":"Int J Antimicrob Agents"},{"key":"3126_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12936-016-1379-2","volume":"15","author":"A Boussaroque","year":"2016","unstructured":"Boussaroque A, Fall B, Madamet M, Wade KA, Fall M, Nakoulima A, et al. Prevalence of anti-malarial resistance genes in Dakar, Senegal from 2013 to 2014. Malar J. 2016;15:347.","journal-title":"Malar J"},{"key":"3126_CR22","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S1097-2765(05)00077-8","volume":"6","author":"DA Fidock","year":"2000","unstructured":"Fidock DA, Nomura T, Talley AK, Cooper RA, Djekunov SM, Ferdig MT, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000;6:861\u201371.","journal-title":"Mol Cell"},{"key":"3126_CR23","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1086\/424469","volume":"190","author":"O Wichmann","year":"2004","unstructured":"Wichmann O, Muehlberger N, Jelinek T, Alifrangis M, Peyerl-Hoffmann G, Muhlen M, et al. Screening for mutations related to atovaquone\/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. J Infect Dis. 2004;190:1541\u20136.","journal-title":"J Infect Dis"},{"key":"3126_CR24","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1128\/JCM.00623-06","volume":"44","author":"B Pradines","year":"2006","unstructured":"Pradines B, Hovette P, Fusai T, Atanda HL, Baret E, Cheval P, et al. Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of Congo. J Clin Microbiol. 2006;44:2404\u20138.","journal-title":"J Clin Microbiol"},{"key":"3126_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1365-3156.2004.01201.x","volume":"9","author":"M Muehlen","year":"2004","unstructured":"Muehlen M, Schreiber J, Ehrhardt S, Otchwemah R, Jelinek T, Bienzle U, et al. Short communication: prevalence of mutations associated with resistance to atovaquone and to the antifolate effect of proguanil in Plasmodium falciparum isolates from northern Ghana. Trop Med Int Health. 2004;9:361\u20133.","journal-title":"Trop Med Int Health"},{"key":"3126_CR26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/1475-2875-6-164","volume":"6","author":"MT Ekala","year":"2007","unstructured":"Ekala MT, Khim N, Legrand E, Randrianarivelojosia M, Jambou R, Fandeur T, et al. Sequence analysis of Plasmodium falciparum cytochrome b in multiple geographic sites. Malar J. 2007;6:164.","journal-title":"Malar J"},{"key":"3126_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1475-2875-5-30","volume":"5","author":"S Pimentel","year":"2006","unstructured":"Pimentel S, Nogueira F, Benchimol C, Quinhentos V, Bom J, Varandas L, et al. Detection of atovaquone\u2013proguanil resistance conferring mutations in Pasmodium falciparum cytochrome b gene in Luanda, Angola. Malar J. 2006;5:30.","journal-title":"Malar J"},{"key":"3126_CR28","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1128\/AAC.02302-15","volume":"60","author":"DL Saunders","year":"2015","unstructured":"Saunders DL, Chaorattanakawee S, Gosi P, Lanteri C, Somethy S, Kuntawunginn W, et al. Atovaquone\u2013proguanil remains a potential stopgap therapy for multidrug-resistant Plasmodium falciparum in areas along the Thai-Cambodian border. Antimicrob Agents Chemother. 2015;60:1896\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"3126_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1475-2875-5-82","volume":"5","author":"CT Happi","year":"2006","unstructured":"Happi CT, Gbotosho GO, Folarin OA, Milner D, Sarr O, Sowunmi A, et al. Confirmation of emergence of mutations associated with atovaquone\u2013proguanil resistance in unexposed Plasmodium falciparum isolates from Africa. Malar J. 2006;5:82.","journal-title":"Malar J"},{"key":"3126_CR30","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1128\/AAC.02550-13","volume":"58","author":"G Cottrell","year":"2014","unstructured":"Cottrell G, Musset L, Hubert V, Le Bras J, Clain J. Emergence of resistance to atovaquone\u2013proguanil in malaria parasites: insights from computational modeling and clinical case reports. Antimicrob Agents Chemother. 2014;58:4504\u201314.","journal-title":"Antimicrob Agents Chemother"},{"key":"3126_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1126\/science.aad9279","volume":"352","author":"CD Goodman","year":"2016","unstructured":"Goodman CD, Siregar JE, Mollard V, Vega-Rodriguez J, Syafruddin D, Matsuoka H, et al. Parasites resistant to the antimalarial atovaquone fail to transmit by mosquitoes. Science. 2016;352:349\u201353.","journal-title":"Science"},{"key":"3126_CR32","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/jac\/dks504","volume":"68","author":"GL Nixon","year":"2013","unstructured":"Nixon GL, Moss DM, Shane AE, Lalloo DG, Fisher N, O\u2019Neill PM, et al. Antimalarial pharmacology and therapeutics of atovaquone. J Antimicrob Chemother. 2013;68:977\u201385.","journal-title":"J Antimicrob Chemother"},{"key":"3126_CR33","doi-asserted-by":"publisher","first-page":"ofz314","DOI":"10.1093\/ofid\/ofz314","volume":"6","author":"M Wojnarski","year":"2019","unstructured":"Wojnarski M, Lon C, Vanachayangkul P, Gosi P, Sok S, Rachmat A, et al. Atovaquone\u2013proguanil in combination with artesunate to treat multidrug-resistant P. falciparum malaria in Cambodia: an open label randomized trial. Open Forum Infect Dis. 2019;6:ofz314.","journal-title":"Open Forum Infect Dis."}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-3126-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12936-020-3126-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-3126-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:13:33Z","timestamp":1611101613000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-020-3126-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,21]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3126"],"URL":"https:\/\/doi.org\/10.1186\/s12936-020-3126-y","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,21]]},"assertion":[{"value":"7 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Bio-banking of human clinical samples used for malaria diagnostics and secondary uses for scientific purposes is possible as long as the corresponding patients are informed and have not indicated any objections. This requirement was fulfilled here by giving verbal information to the patients, and no immediate or delayed patient opposition was reported to the hospital clinicians. Informed consent was not required for this study because the sampling procedures and testing are part of the French national recommendations for the care and surveillance of malaria. This work was performed under the statutory auspices of the French national reference centre for imported malaria, and isolates were anonymized by re-coding.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}